Agilent Posts 19 Percent Jump in Q1 Life Sciences Revenues Driven by LC, Mass Spec Sales | GenomeWeb

Agilent Technologies this week posted a 25 percent year-over-year increase in revenues for the first quarter of 2011, including a 19 percent rise in revenues in its Life Sciences segment.

The Life Sciences jump was driven by strong sales in liquid chromatography and mass spectrometry platforms due in part to an acceleration in the instrument replacement cycle, CEO Bill Sullivan said on an investor call discussing the company's earnings.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.